Equities

RPG Life Sciences Limited

RPGLIFE:NSI

RPG Life Sciences Limited

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,250.00
  • Today's Change0.00 / 0.00%
  • Shares traded33.00
  • 1 Year change+53.57%
  • Beta1.0318
Data delayed at least 15 minutes, as of Nov 13 2024 03:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,2591,162698
Total Receivables, Net643375460
Total Inventory1,036951906
Prepaid expenses31--0.80
Other current assets, total121544.60
Total current assets2,9812,6412,069
Property, plant & equipment, net1,8181,1631,001
Goodwill, net------
Intangibles, net280334347
Long term investments10--3.80
Note receivable - long term291914
Other long term assets4.303712
Total assets5,1294,1943,446
LIABILITIES
Accounts payable710647455
Accrued expenses292--105
Notes payable/short-term debt00.102.80
Current portion long-term debt/capital leases003.60
Other current liabilities, total308381235
Total current liabilities1,3101,028801
Total long term debt003.00
Total debt00.109.40
Deferred income tax--2023
Minority interest------
Other liabilities, total717062
Total liabilities1,3801,118888
SHAREHOLDERS EQUITY
Common stock132132132
Additional paid-in capital345--345
Retained earnings (accumulated deficit)3,2722,9442,081
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity3,7493,0762,558
Total liabilities & shareholders' equity5,1294,1943,446
Total common shares outstanding171717
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.